HCW Biologics strengthens U.S. patent estate for HCW9302 alopecia areata
HCW Biologics says it has strengthened its U.S. patent estate for HCW9302, its lead clinical-stage immunotherapeutic for alopecia areata.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.